AstraZeneca’s COVID-19 Taskforce Starts With Calquence Trial
BTK Inhibitor Has Shown Results In Advanced COVID-19 Lung Disease
AstraZeneca will launch a global clinical trial for its blood cancer drug Calquence because it showed early respiratory promise in later-stage COVID-19 patients, those in intensive care units and on ventilators.
You may also be interested in...
At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.
AstraZeneca, during a strong first-quarter update, underscored its determination to test existing portfolio assets for use in fighting the COVID-19 pandemic.
The first of six new compounds are expected to begin Phase II testing soon as part of the UK’s ACCORD initiative, a randomized platform trial bringing together government, industry and research organisations to find potential treatments for COVID-19.